10:09 PM
 | 
Jun 15, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from 36 patients with non-Hodgkin’s lymphoma (NHL) or advanced solid tumors in the dose-escalation Phase I portion of a Phase I/II trial showing that oral ASN002 was well tolerated. Pneumonia was reported as a dose-limiting toxicity (DLT) at the twice-daily 100 mg dose of ASN002. The recommended Phase II...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >